Last checked at Today 10:02
LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News5
AZN Share
Chat
AZN Share
Trades8,006
AZN
Live RNS2
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,160.00
Bid:
12,160.00
Ask:
12,162.00
Change:
172.00 (1.43%)
Spread:
2.00 (0.016%)
Open:
12,254.00
High:
12,256.00
Low:
12,052.00
Prev. Close:
11,988.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.AstraZeneca sells antibiotics business to Pfizer for £1.2bn
Wed, 24th Aug 2016 07:11
(ShareCast News) - AstraZeneca has agreed to sell its antibiotics business to US giant Pfizer for staged payments amounting to $1.6bn (£1.2bn) plus recurring, double-digit royalties on future sales.The FTSE 100 group said the sale would reinforces its focus on developing medicines in its three main therapy areas, while realising value from what it said was a strong portfolio of established and late-stage antibiotics through Pfizer's commercialisation and development abilities.An up-front payment of $550m on completion of the deal, which is expected in the fourth quarter of 2016, will be followed by an unconditional payment of $175m in January 2019 for the commercialisation and development rights to approved antibiotics Merrem, Zinforo and Zavicefta, as well as two still in development, ATM-AVI and CXL.Furthermore, Pfizer will pay up to $250m in commercial, manufacturing and regulatory milestones, up to $600m in sales-related payments as well as recurring, double-digit royalties on future sales of Zavicefta and ATM-AVI in certain markets.AstraZeneca, which generated product sales from Merrem and Zinforo in 2015 of $250m, said the agreement does not impact its financial guidance for 2016 and stressed that MedImmune's portfolio of biologic products such as FluMis and Synagis, and AstraZeneca's stake in Entasis Therapeutics, spun-off in 2015 and now operating as a stand-alone company, are not included as part of the agreement."This agreement reinforces our strategic focus to invest in our three main therapy areas where we can make the greatest difference to patients' lives," said Luke Miels, AstraZeneca's executive vice president for Europe and head of the antibiotics business unit."We're pleased that our strong science in antibiotics will continue to serve a critical public health need through Pfizer's dedicated focus on infectious diseases, ensuring these important medicines reach greater numbers of patients around the world."
More News
Today 09:13
AstraZeneca makes progress with Truqap and Enhertu cancer treatments
(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.
Read moreToday 07:50
LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid
(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.
Read moreToday 07:24
AstraZeneca makes progress with two breast cancer treatments
(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.
Read more26 Apr 2024 09:33
LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:
Read more25 Apr 2024 16:57
LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge
(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.
Read more25 Apr 2024 15:14
London close: Stocks finish mixed as US GDP growth slows
(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.
Read more25 Apr 2024 11:50
LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American
(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.
Read more25 Apr 2024 10:33
25 Apr 2024 09:18
TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth
(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.
Read more25 Apr 2024 09:12
LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP
(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.
Read more25 Apr 2024 08:38
AstraZeneca blows past analysts' estimates for Q1
(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.
Read more25 Apr 2024 07:56
REPEAT: Miner Anglo American reviews takeover bid from rival BHP
(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.
Read more25 Apr 2024 07:52
Sanofi profit slips on generic competition and currency effects
April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.
Read more25 Apr 2024 07:43
LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover
(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.
Read more